Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Similar articles for PubMed (Select 12644826)

1.

L523S, an RNA-binding protein as a potential therapeutic target for lung cancer.

Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG.

Br J Cancer. 2003 Mar 24;88(6):887-94.

2.

L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma.

Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, Reed SG.

Oncogene. 2001 Nov 22;20(53):7699-709.

3.

Increased expression of the LGALS3 (galectin 3) gene in human non-small-cell lung cancer.

Yoshimura A, Gemma A, Hosoya Y, Komaki E, Hosomi Y, Okano T, Takenaka K, Matuda K, Seike M, Uematsu K, Hibino S, Shibuya M, Yamada T, Hirohashi S, Kudoh S.

Genes Chromosomes Cancer. 2003 Jun;37(2):159-64.

PMID:
12696064
4.

Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas.

Pryor JG, Simon RA, Bourne PA, Spaulding BO, Scott GA, Xu H.

Hum Pathol. 2009 Feb;40(2):238-43. doi: 10.1016/j.humpath.2008.07.009. Epub 2008 Oct 5.

PMID:
18835627
5.

Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer.

Kato T, Hayama S, Yamabuki T, Ishikawa N, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):434-42.

6.

Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.

Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, Pappen B, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, Cheever MA.

Mol Ther. 2006 Jun;13(6):1185-91. Epub 2006 Apr 11.

PMID:
16581300
7.

Reduced transcription of the RB2/p130 gene in human lung cancer.

Xue Jun H, Gemma A, Hosoya Y, Matsuda K, Nara M, Hosomi Y, Okano T, Kurimoto F, Seike M, Takenaka K, Yoshimura A, Toyota M, Kudoh S.

Mol Carcinog. 2003 Nov;38(3):124-9.

PMID:
14587097
8.

Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.

Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.

Lung Cancer. 2008 Oct;62(1):113-9. doi: 10.1016/j.lungcan.2008.02.014. Epub 2008 Jun 11.

PMID:
18550205
9.

Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays.

Wikman H, Seppänen JK, Sarhadi VK, Kettunen E, Salmenkivi K, Kuosma E, Vainio-Siukola K, Nagy B, Karjalainen A, Sioris T, Salo J, Hollmén J, Knuutila S, Anttila S.

J Pathol. 2004 May;203(1):584-93.

PMID:
15095482
10.

Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction.

Sueoka E, Sueoka N, Iwanaga K, Sato A, Suga K, Hayashi S, Nagasawa K, Nakachi K.

Lung Cancer. 2005 Apr;48(1):77-83. Epub 2004 Dec 13.

PMID:
15777973
11.

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M.

J Clin Oncol. 2009 Apr 20;27(12):2030-7. doi: 10.1200/JCO.2008.19.4134. Epub 2009 Mar 9.

12.

Aspects of lung cancer gene expression profiling.

Müller-Hagen G, Beinert T, Sommer A.

Curr Opin Drug Discov Devel. 2004 May;7(3):290-303. Review.

PMID:
15216932
13.

Overexpression of RhoE in Non-small Cell Lung Cancer (NSCLC) is associated with smoking and correlates with DNA copy number changes.

Cuiyan Z, Jie H, Fang Z, Kezhi Z, Junting W, Susheng S, Xiaoli F, Ning L, Xinhua M, Zhaoli C, Kang S, Bin Q, Baozhong L, Sheng C, Meihua X, Jie H.

Cancer Biol Ther. 2007 Mar;6(3):335-42. Epub 2007 Mar 4.

14.

Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.

Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS, Song LB.

Cancer. 2009 Apr 1;115(7):1507-17. doi: 10.1002/cncr.24128.

15.

Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer.

Chong IW, Chang MY, Chang HC, Yu YP, Sheu CC, Tsai JR, Hung JY, Chou SH, Tsai MS, Hwang JJ, Lin SR.

Oncol Rep. 2006 Nov;16(5):981-8.

PMID:
17016581
16.

pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis.

Russo G, Claudio PP, Fu Y, Stiegler P, Yu Z, Macaluso M, Giordano A.

Oncogene. 2003 Oct 9;22(44):6959-69.

PMID:
14534545
17.

Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.

Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K.

Lung Cancer. 2005 May;48(2):281-9. Epub 2004 Dec 22.

PMID:
15829330
18.

A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.

Krueger P, Nitz C, Foster R, MacDonald C, Gelber O, Lalehzadeh G, Goodson R, Winter J, Gelber C.

Cancer Immunol Immunother. 2003 Jun;52(6):367-77. Epub 2003 Apr 1.

PMID:
12669243
19.

A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.

Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, Yang YP, Wu CY, Shih FY, Liu CC, Lin HP, Jou YS, Lin SC, Lin CW, Chen WJ, Chan WK, Chen JJ, Yang PC.

J Natl Cancer Inst. 2006 Jun 21;98(12):825-38.

20.

Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.

Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K, Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N, Sato N.

Clin Cancer Res. 2005 Feb 1;11(3):1000-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk